Finance

Lists
Why is 3696 up 3,88%?
Dive Deeper
3696:HKG
Insilico Medicine Cayman TopCo
39,10 HKD
+3,88%
(+1,46) 1D
16-окт., 16:08:14 GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 3696...
Open
39,16 HKD
High
40,28 HKD
Low
38,12 HKD
Mkt. cap
22,88 млд
Avg. vol.
15,66 млн
Volume
15,71 млн
52-wk high
80,90 HKD
52-wk low
29,98 HKD
EPS
-4,20 HKD
Shares outstanding
557,42 млн
No. of employees
333
Open
39,16 HKD
High
40,28 HKD
Low
38,12 HKD
Mkt. cap
22,88 млд
Avg. vol.
15,66 млн
Volume
15,71 млн
52-wk high
80,90 HKD
52-wk low
29,98 HKD
EPS
-4,20 HKD
Shares outstanding
557,42 млн
No. of employees
333
News stories
From web sources and news partners
Profile
Insilico Medicine is a biotechnology company headquartered in Boston, Massachusetts, with additional facilities in Pak Shek Kok, Hong Kong in Hong Kong Science Park near the Chinese University of Hong Kong, and in New York, at The Cure by Deerfield. The company applies genomics, big data analysis, and deep learning for in silico drug discovery. Wikipedia
About Insilico Medicine Cayman TopCo
CEOFeng Ren | Alex Zhavoronkov
Employees333
Founded2014
Headquarters-
SectorHealth care
Last report
2026-ж., 26-авг.
Fiscal period
Q2 2026
- / -
Revenue / Est. (USD)
53,15 млн / -
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
14,39 млн
14,39 млн
53,15 млн
53,15 млн
Cost of goods sold
2,98 млн
2,98 млн
5,17 млн
5,17 млн
Cost of revenue
2,98 млн
2,98 млн
5,17 млн
5,17 млн
Research and development expenses
22,90 млн
22,90 млн
24,66 млн
24,66 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7,05 млн
7,05 млн
9,47 млн
9,47 млн
Operating expense
30,23 млн
30,23 млн
33,85 млн
33,85 млн
Total operating expenses
33,20 млн
33,20 млн
39,02 млн
39,02 млн
Operating income
-18,81 млн
-18,81 млн
14,14 млн
14,14 млн
Other non operating income
-149,82 млн
-149,82 млн
1,50 миң
1,50 миң
EBT including unusual items
-166,54 млн
-166,54 млн
17,91 млн
17,91 млн
EBT excluding unusual items
-167,61 млн
-167,61 млн
16,57 млн
16,57 млн
Income tax expense
9,50 миң
9,50 миң
139,50 миң
139,50 миң
Effective tax rate
-0,01%
-0,01%
0,78%
0,78%
Other operating expenses
-
-
-
-
Net income
-166,55 млн
-166,55 млн
17,77 млн
17,77 млн
Net profit margin
-1 157,28%
-1 157,28%
33,43%
33,43%
Earnings per share
-
-
-
-
Interest and investment income
1,29 млн
1,29 млн
3,89 млн
3,89 млн
Interest expense
-56,00 миң
-56,00 миң
-83,00 миң
-83,00 миң
Net interest expenses
1,24 млн
1,24 млн
3,81 млн
3,81 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-18,08 млн
-18,08 млн
14,89 млн
14,89 млн
Gain or loss from assets sale
63,50 миң
63,50 миң
-
-
AI content may include mistakes. Learn more
Google колдонмолору